{"abstracts-retrieval-response": {"item": {"ait:process-info": {"ait:status": {"@state": "update", "@type": "core", "@stage": "S300"}, "ait:date-delivered": {"@day": "25", "@timestamp": "2024-10-25T18:49:40.000040-04:00", "@year": "2024", "@month": "10"}, "ait:date-sort": {"@day": "01", "@year": "2017", "@month": "12"}}, "xocs:meta": {"xocs:funding-list": {"@pui-match": "primary", "@has-funding-info": "1", "xocs:funding-addon-generated-timestamp": "2019-03-01T15:37:07.393Z", "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/nlp"}}, "bibrecord": {"head": {"author-group": [{"affiliation": {"country": "United States", "@afid": "60005558", "@country": "usa", "city": "Rochester", "organization": [{"$": "Division of Gastroenterology and Hepatology"}, {"$": "Mayo Clinic"}], "affiliation-id": {"@afid": "60005558", "@dptid": "113524906"}, "state": "MN", "@dptid": "113524906"}, "author": [{"ce:given-name": "Sang Hyoung", "preferred-name": {"ce:given-name": "Sang Hyoung", "ce:initials": "S.H.", "ce:surname": "Park", "ce:indexed-name": "Park S.H."}, "@seq": "1", "ce:initials": "S.H.", "@date-locked": "2022-12-02T09:12:28.968", "@_fa": "true", "@type": "auth", "ce:surname": "Park", "@auid": "34977204700", "ce:indexed-name": "Park S.H."}, {"ce:given-name": "Satimai", "preferred-name": {"ce:given-name": "Satimai", "ce:initials": "S.", "ce:surname": "Aniwan", "ce:indexed-name": "Aniwan S."}, "@seq": "2", "ce:initials": "S.", "@_fa": "true", "@type": "auth", "ce:surname": "Aniwan", "@auid": "36010544000", "ce:indexed-name": "Aniwan S."}, {"ce:given-name": "Edward V", "preferred-name": {"ce:given-name": "Edward V.", "ce:initials": "E.V.", "ce:surname": "Loftus", "ce:indexed-name": "Loftus E.V."}, "@seq": "3", "ce:initials": "E.V.", "@date-locked": "2018-02-27T15:09:58.459", "@_fa": "true", "@type": "auth", "ce:surname": "Loftus", "@auid": "7202138774", "ce:suffix": "Jr", "ce:indexed-name": "Loftus E.V."}]}, {"affiliation": {"country": "South Korea", "@afid": "60006240", "@country": "kor", "city": "Seoul", "organization": [{"$": "Department of Gastroenterology"}, {"$": "University of Ulsan College of Medicine"}, {"$": "Asan Medical Center"}], "affiliation-id": [{"@afid": "60006240", "@dptid": "113669103"}, {"@afid": "60068691"}], "@dptid": "113669103"}, "author": [{"ce:given-name": "Sang Hyoung", "preferred-name": {"ce:given-name": "Sang Hyoung", "ce:initials": "S.H.", "ce:surname": "Park", "ce:indexed-name": "Park S.H."}, "@seq": "1", "ce:initials": "S.H.", "@date-locked": "2022-12-02T09:12:28.968", "@_fa": "true", "@type": "auth", "ce:surname": "Park", "@auid": "34977204700", "ce:indexed-name": "Park S.H."}]}, {"affiliation": {"country": "Thailand", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Division of Gastroenterology"}, {"$": "Chulalongkorn University"}, {"$": "King Chulalongkorn Memorial Hospital"}, {"$": "Thai Red Cross Society"}], "affiliation-id": [{"@afid": "60028190", "@dptid": "104425746"}, {"@afid": "60031780"}, {"@afid": "60022183"}], "@dptid": "104425746"}, "author": [{"ce:given-name": "Satimai", "preferred-name": {"ce:given-name": "Satimai", "ce:initials": "S.", "ce:surname": "Aniwan", "ce:indexed-name": "Aniwan S."}, "@seq": "2", "ce:initials": "S.", "@_fa": "true", "@type": "auth", "ce:surname": "Aniwan", "@auid": "36010544000", "ce:indexed-name": "Aniwan S."}]}], "citation-title": "Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease", "abstracts": "\u00a9 2017 Elsevier LtdFor the ultimate aim of preventing intestinal disability in inflammatory bowel disease (IBD), the treatment goal has moved from symptom control towards inflammation control (i.e., \u2018deep remission\u2019). Furthermore, the concept of \u2018treat-to-target\u2019 has been adopted to assist in treatment escalation and better control. Although deep remission is possible with current biologics, there are still unmet needs in IBD management. Biosimilars of several biologics will be an increasingly common option in the near future. In this review, we review the current status of novel drugs for IBD, focusing on recent phase 2 and 3 randomized controlled trials, and address the issues of biosimilars. Recent studies of the \u2018treat-to-target\u2019 strategy and therapeutic drug monitoring are summarized.", "citation-info": {"citation-type": {"@code": "re"}, "citation-language": {"@language": "English", "@xml:lang": "eng"}, "abstract-language": {"@language": "English", "@xml:lang": "eng"}}, "source": {"codencode": "COPUB", "sourcetitle-abbrev": "Curr. Opin. Pharmacol.", "@country": "gbr", "translated-sourcetitle": {"$": "Current Opinion in Pharmacology", "@xml:lang": "eng"}, "issn": [{"$": "14714973", "@type": "electronic"}, {"$": "14714892", "@type": "print"}], "volisspag": {"voliss": {"@volume": "37"}, "pagerange": {"@first": "65", "@last": "71"}}, "@type": "j", "publicationyear": {"@first": "2017"}, "publisher": {"publishername": "Elsevier Ltd"}, "sourcetitle": "Current Opinion in Pharmacology", "@srcid": "20681", "publicationdate": {"month": "12", "year": "2017", "date-text": "December 2017", "day": "01"}}, "enhancement": {"classificationgroup": {"classifications": [{"@type": "EMCLASS", "classification": [{"classification-code": "30", "classification-description": "Clinical and Experimental Pharmacology"}, {"classification-code": "37", "classification-description": "Drug Literature Index"}, {"classification-code": "38", "classification-description": "Adverse Reactions Titles"}, {"classification-code": "48", "classification-description": "Gastroenterology"}]}, {"@type": "ASJC", "classification": [{"$": "3004"}, {"$": "3002"}]}, {"@type": "SUBJABBR", "classification": "PHAR"}]}, "tradenamegroup": {"tradenames": {"trademanuitem": [{"tradename": "abt 494"}, {"tradename": "bi 655066"}, {"tradename": "ct p 13"}, {"tradename": "medi 2070"}, {"tradename": "pf 00547659"}], "@type": "TNM"}}, "chemicalgroup": {"chemicals": [{"@source": "esbd", "chemical": [{"cas-registry-number": [{"$": "331731-18-1"}, {"$": "1446410-95-2"}], "chemical-name": "adalimumab"}, {"cas-registry-number": "1610353-18-8", "chemical-name": "brazikumab"}, {"cas-registry-number": "1044758-60-2", "chemical-name": "etrolizumab"}, {"cas-registry-number": [{"$": "1206161-97-8"}, {"$": "1540859-07-1"}], "chemical-name": "filgotinib"}, {"cas-registry-number": "476181-74-5", "chemical-name": "golimumab"}, {"cas-registry-number": "170277-31-3", "chemical-name": "infliximab"}, {"cas-registry-number": [{"$": "1443994-46-4"}, {"$": "1443994-98-6"}], "chemical-name": "mongersen"}, {"cas-registry-number": [{"$": "1306760-87-1"}, {"$": "1618636-37-5"}], "chemical-name": "ozanimod"}, {"cas-registry-number": "1612838-76-2", "chemical-name": "risankizumab"}, {"cas-registry-number": [{"$": "477600-75-2"}, {"$": "540737-29-9"}], "chemical-name": "tofacitinib"}, {"cas-registry-number": [{"$": "1310726-60-3"}, {"$": "1607431-21-9"}], "chemical-name": "upadacitinib"}, {"cas-registry-number": [{"$": "815610-63-0"}, {"$": "949907-93-1"}], "chemical-name": "ustekinumab"}, {"cas-registry-number": "943609-66-3", "chemical-name": "vedolizumab"}]}, {"@source": "nlm", "chemical": [{"chemical-name": "Anti-Inflammatory Agents"}, {"chemical-name": "Biological Products"}, {"chemical-name": "Biosimilar Pharmaceuticals"}]}]}}}, "item-info": {"copyright": {"$": "Copyright 2018 Elsevier B.V., All rights reserved.", "@type": "Elsevier"}, "external-source": "MEDLINE", "dbcollection": [{"$": "EMBASE"}, {"$": "MEDL"}, {"$": "REAXYS"}, {"$": "REAXYSCAR"}, {"$": "RMC"}, {"$": "SCOPUS"}, {"$": "Scopusbase"}], "history": {"date-created": {"@day": "08", "@timestamp": "BST 12:09:02", "@year": "2018", "@month": "08"}}, "itemidlist": {"itemid": [{"$": "618548624", "@idtype": "PUI"}, {"$": "723275299", "@idtype": "CAR-ID"}, {"$": "20170706241", "@idtype": "EMBASE"}, {"$": "28992449", "@idtype": "MEDL"}, {"$": "2017222341", "@idtype": "REAXYS"}, {"$": "20171771611", "@idtype": "REAXYSCAR"}, {"$": "2017284752", "@idtype": "RMC"}, {"$": "20170635878", "@idtype": "SCOPUS"}, {"$": "85030719959", "@idtype": "SCP"}, {"$": "85030719959", "@idtype": "SGR"}, {"$": "623359324", "@idtype": "PUIsecondary"}], "ce:pii": "S1471489217300619", "ce:doi": "10.1016/j.coph.2017.09.007"}}, "tail": {"bibliography": {"@refcount": "52", "reference": [{"ref-fulltext": "Peyrin-Biroulet, L., Harmsen, W.S., Tremaine, W.J., Zinsmeister, A.R., Sandborn, W.J., Loftus, E.V. Jr., Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970\u20132004). Am J Gastroenterol 107 (2012), 1693\u20131701.", "@id": "1", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970\u20132004)"}, "refd-itemidlist": {"itemid": [{"$": "bib0265", "@idtype": "FRAGMENTID"}, {"$": "84869502569", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "107"}, "pagerange": {"@first": "1693", "@last": "1701"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Peyrin-Biroulet", "ce:indexed-name": "Peyrin-Biroulet L."}, {"@seq": "2", "ce:initials": "W.S.", "@_fa": "true", "ce:surname": "Harmsen", "ce:indexed-name": "Harmsen W.S."}, {"@seq": "3", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Tremaine", "ce:indexed-name": "Tremaine W.J."}, {"@seq": "4", "ce:initials": "A.R.", "@_fa": "true", "ce:surname": "Zinsmeister", "ce:indexed-name": "Zinsmeister A.R."}, {"@seq": "5", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W.J."}, {"@seq": "6", "ce:initials": "E.V.", "@_fa": "true", "ce:surname": "Loftus", "ce:suffix": "Jr.", "ce:indexed-name": "Loftus E.V."}]}, "ref-sourcetitle": "Am J Gastroenterol"}}, {"ref-fulltext": "Samuel, S., Ingle, S.B., Dhillon, S., Yadav, S., Harmsen, W.S., Zinsmeister, A.R., Tremaine, W.J., Sandborn, W.J., Loftus, E.V. Jr., Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis 19 (2013), 1858\u20131866.", "@id": "2", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis"}, "refd-itemidlist": {"itemid": [{"$": "bib0270", "@idtype": "FRAGMENTID"}, {"$": "84883855280", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "19"}, "pagerange": {"@first": "1858", "@last": "1866"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Samuel", "ce:indexed-name": "Samuel S."}, {"@seq": "2", "ce:initials": "S.B.", "@_fa": "true", "ce:surname": "Ingle", "ce:indexed-name": "Ingle S.B."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Dhillon", "ce:indexed-name": "Dhillon S."}, {"@seq": "4", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Yadav", "ce:indexed-name": "Yadav S."}, {"@seq": "5", "ce:initials": "W.S.", "@_fa": "true", "ce:surname": "Harmsen", "ce:indexed-name": "Harmsen W.S."}, {"@seq": "6", "ce:initials": "A.R.", "@_fa": "true", "ce:surname": "Zinsmeister", "ce:indexed-name": "Zinsmeister A.R."}, {"@seq": "7", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Tremaine", "ce:indexed-name": "Tremaine W.J."}, {"@seq": "8", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W.J."}, {"@seq": "9", "ce:initials": "E.V.", "@_fa": "true", "ce:surname": "Loftus", "ce:suffix": "Jr.", "ce:indexed-name": "Loftus E.V."}]}, "ref-sourcetitle": "Inflamm Bowel Dis"}}, {"ref-fulltext": "Thia, K.T., Sandborn, W.J., Harmsen, W.S., Zinsmeister, A.R., Loftus, E.V. Jr., Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 139 (2010), 1147\u20131155.", "@id": "3", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort"}, "refd-itemidlist": {"itemid": [{"$": "bib0275", "@idtype": "FRAGMENTID"}, {"$": "77957346794", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "139"}, "pagerange": {"@first": "1147", "@last": "1155"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "K.T.", "@_fa": "true", "ce:surname": "Thia", "ce:indexed-name": "Thia K.T."}, {"@seq": "2", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W.J."}, {"@seq": "3", "ce:initials": "W.S.", "@_fa": "true", "ce:surname": "Harmsen", "ce:indexed-name": "Harmsen W.S."}, {"@seq": "4", "ce:initials": "A.R.", "@_fa": "true", "ce:surname": "Zinsmeister", "ce:indexed-name": "Zinsmeister A.R."}, {"@seq": "5", "ce:initials": "E.V.", "@_fa": "true", "ce:surname": "Loftus", "ce:suffix": "Jr.", "ce:indexed-name": "Loftus E.V."}]}, "ref-sourcetitle": "Gastroenterology"}}, {"ref-fulltext": "Levesque, B.G., Sandborn, W.J., Ruel, J., Feagan, B.G., Sands, B.E., Colombel, J.F., Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology, 148, 2015 37-51 e31.", "@id": "4", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Converging goals of treatment of inflammatory bowel disease from clinical trials and practice"}, "refd-itemidlist": {"itemid": [{"$": "bib0280", "@idtype": "FRAGMENTID"}, {"$": "84922890759", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "148"}}, "ref-text": "37-51 e31", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.G.", "@_fa": "true", "ce:surname": "Levesque", "ce:indexed-name": "Levesque B.G."}, {"@seq": "2", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W.J."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Ruel", "ce:indexed-name": "Ruel J."}, {"@seq": "4", "ce:initials": "B.G.", "@_fa": "true", "ce:surname": "Feagan", "ce:indexed-name": "Feagan B.G."}, {"@seq": "5", "ce:initials": "B.E.", "@_fa": "true", "ce:surname": "Sands", "ce:indexed-name": "Sands B.E."}, {"@seq": "6", "ce:initials": "J.F.", "@_fa": "true", "ce:surname": "Colombel", "ce:indexed-name": "Colombel J.F."}]}, "ref-sourcetitle": "Gastroenterology"}}, {"ref-fulltext": "Feagan, B.G., Sandborn, W.J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J.R., Blank, M.A., Johanns, J., Gao, L.L., Miao, Y., et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 375 (2016), 1946\u20131960 Integrated randomized clinical trials of ustekinumab demonstrating its effectiveness for induction and maintenance of remission in moderate to severe Crohn's disease (both patients who had failed conventional therapy and those who had failed anti-TNF therapy).", "@id": "5", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "Ustekinumab as induction and maintenance therapy for Crohn's disease"}, "refd-itemidlist": {"itemid": [{"$": "bib0285", "@idtype": "FRAGMENTID"}, {"$": "84995563335", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "375"}, "pagerange": {"@first": "1946", "@last": "1960"}}, "ref-text": "Integrated randomized clinical trials of ustekinumab demonstrating its effectiveness for induction and maintenance of remission in moderate to severe Crohn's disease (both patients who had failed conventional therapy and those who had failed anti-TNF therapy).", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.G.", "@_fa": "true", "ce:surname": "Feagan", "ce:indexed-name": "Feagan B.G."}, {"@seq": "2", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W.J."}, {"@seq": "3", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Gasink", "ce:indexed-name": "Gasink C."}, {"@seq": "4", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Jacobstein", "ce:indexed-name": "Jacobstein D."}, {"@seq": "5", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Lang", "ce:indexed-name": "Lang Y."}, {"@seq": "6", "ce:initials": "J.R.", "@_fa": "true", "ce:surname": "Friedman", "ce:indexed-name": "Friedman J.R."}, {"@seq": "7", "ce:initials": "M.A.", "@_fa": "true", "ce:surname": "Blank", "ce:indexed-name": "Blank M.A."}, {"@seq": "8", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Johanns", "ce:indexed-name": "Johanns J."}, {"@seq": "9", "ce:initials": "L.L.", "@_fa": "true", "ce:surname": "Gao", "ce:indexed-name": "Gao L.L."}, {"@seq": "10", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Miao", "ce:indexed-name": "Miao Y."}], "et-al": null}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "STELARA\u00ae(ustekinumab) Prescribing Information. 2016 September, Janssen Biotech, Inc, Horsham, PA 19044.", "@id": "6", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "STELARA\u00ae(ustekinumab) Prescribing Information"}, "refd-itemidlist": {"itemid": [{"$": "bib0290", "@idtype": "FRAGMENTID"}, {"$": "85030707123", "@idtype": "SGR"}]}, "ref-text": "Janssen Biotech, Inc Horsham, PA 19044"}}, {"ref-fulltext": "Sands, B.E., Chen, J., Feagan, B.G., Penney, M., Rees, W.A., Danese, S., Higgins, P.D.R., Newbold, P., Faggioni, R., Patra, K., et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn's disease: a phase 2a study. Gastroenterology, 153, 2017 77-86 e76.", "@id": "7", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn's disease: a phase 2a study"}, "refd-itemidlist": {"itemid": [{"$": "bib0295", "@idtype": "FRAGMENTID"}, {"$": "85020929772", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "153"}}, "ref-text": "77-86 e76", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.E.", "@_fa": "true", "ce:surname": "Sands", "ce:indexed-name": "Sands B.E."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Chen", "ce:indexed-name": "Chen J."}, {"@seq": "3", "ce:initials": "B.G.", "@_fa": "true", "ce:surname": "Feagan", "ce:indexed-name": "Feagan B.G."}, {"@seq": "4", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Penney", "ce:indexed-name": "Penney M."}, {"@seq": "5", "ce:initials": "W.A.", "@_fa": "true", "ce:surname": "Rees", "ce:indexed-name": "Rees W.A."}, {"@seq": "6", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Danese", "ce:indexed-name": "Danese S."}, {"@seq": "7", "ce:initials": "P.D.R.", "@_fa": "true", "ce:surname": "Higgins", "ce:indexed-name": "Higgins P.D.R."}, {"@seq": "8", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Newbold", "ce:indexed-name": "Newbold P."}, {"@seq": "9", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Faggioni", "ce:indexed-name": "Faggioni R."}, {"@seq": "10", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Patra", "ce:indexed-name": "Patra K."}], "et-al": null}, "ref-sourcetitle": "Gastroenterology"}}, {"ref-fulltext": "Feagan, B.G., Sandborn, W.J., D'Haens, G., Panes, J., Kaser, A., Ferrante, M., Louis, E., Franchimont, D., Dewit, O., Seidler, U., et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 389 (2017), 1699\u20131709.", "@id": "8", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study"}, "refd-itemidlist": {"itemid": [{"$": "bib0300", "@idtype": "FRAGMENTID"}, {"$": "85017435425", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "389"}, "pagerange": {"@first": "1699", "@last": "1709"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.G.", "@_fa": "true", "ce:surname": "Feagan", "ce:indexed-name": "Feagan B.G."}, {"@seq": "2", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W.J."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "D'Haens", "ce:indexed-name": "D'Haens G."}, {"@seq": "4", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Panes", "ce:indexed-name": "Panes J."}, {"@seq": "5", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Kaser", "ce:indexed-name": "Kaser A."}, {"@seq": "6", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Ferrante", "ce:indexed-name": "Ferrante M."}, {"@seq": "7", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Louis", "ce:indexed-name": "Louis E."}, {"@seq": "8", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Franchimont", "ce:indexed-name": "Franchimont D."}, {"@seq": "9", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Dewit", "ce:indexed-name": "Dewit O."}, {"@seq": "10", "ce:initials": "U.", "@_fa": "true", "ce:surname": "Seidler", "ce:indexed-name": "Seidler U."}], "et-al": null}, "ref-sourcetitle": "Lancet"}}, {"ref-fulltext": "Sandborn, W.J., Ghosh, S., Panes, J., Vranic, I., Wang, W., Niezychowski, W., Study, A.I., A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol, 12, 2014 1485-1493 e1482.", "@id": "9", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease"}, "refd-itemidlist": {"itemid": [{"$": "bib0305", "@idtype": "FRAGMENTID"}, {"$": "84906792069", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "12"}}, "ref-text": "1485-1493 e1482", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W.J."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Ghosh", "ce:indexed-name": "Ghosh S."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Panes", "ce:indexed-name": "Panes J."}, {"@seq": "4", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Vranic", "ce:indexed-name": "Vranic I."}, {"@seq": "5", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Wang", "ce:indexed-name": "Wang W."}, {"@seq": "6", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Niezychowski", "ce:indexed-name": "Niezychowski W."}, {"@seq": "7", "ce:initials": "A.I.", "@_fa": "true", "ce:surname": "Study", "ce:indexed-name": "Study A.I."}]}, "ref-sourcetitle": "Clin Gastroenterol Hepatol"}}, {"ref-fulltext": "Panes, J., Sandborn, W.J., Schreiber, S., Sands, B.E., Vermeire, S., D'Haens, G., Panaccione, R., Higgins, P.D.R., Colombel, J.F., Feagan, B.G., et al. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut 66 (2017), 1049\u20131059.", "@id": "10", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials"}, "refd-itemidlist": {"itemid": [{"$": "bib0310", "@idtype": "FRAGMENTID"}, {"$": "85019469954", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "66"}, "pagerange": {"@first": "1049", "@last": "1059"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Panes", "ce:indexed-name": "Panes J."}, {"@seq": "2", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W.J."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Schreiber", "ce:indexed-name": "Schreiber S."}, {"@seq": "4", "ce:initials": "B.E.", "@_fa": "true", "ce:surname": "Sands", "ce:indexed-name": "Sands B.E."}, {"@seq": "5", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Vermeire", "ce:indexed-name": "Vermeire S."}, {"@seq": "6", "ce:initials": "G.", "@_fa": "true", "ce:surname": "D'Haens", "ce:indexed-name": "D'Haens G."}, {"@seq": "7", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Panaccione", "ce:indexed-name": "Panaccione R."}, {"@seq": "8", "ce:initials": "P.D.R.", "@_fa": "true", "ce:surname": "Higgins", "ce:indexed-name": "Higgins P.D.R."}, {"@seq": "9", "ce:initials": "J.F.", "@_fa": "true", "ce:surname": "Colombel", "ce:indexed-name": "Colombel J.F."}, {"@seq": "10", "ce:initials": "B.G.", "@_fa": "true", "ce:surname": "Feagan", "ce:indexed-name": "Feagan B.G."}], "et-al": null}, "ref-sourcetitle": "Gut"}}, {"ref-fulltext": "Vermeire, S., Schreiber, S., Petryka, R., Kuehbacher, T., Hebuterne, X., Roblin, X., Klopocka, M., Goldis, A., Wisniewska-Jarosinska, M., Baranovsky, A., et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 389 (2017), 266\u2013275.", "@id": "11", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial"}, "refd-itemidlist": {"itemid": [{"$": "bib0315", "@idtype": "FRAGMENTID"}, {"$": "85008324875", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "389"}, "pagerange": {"@first": "266", "@last": "275"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Vermeire", "ce:indexed-name": "Vermeire S."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Schreiber", "ce:indexed-name": "Schreiber S."}, {"@seq": "3", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Petryka", "ce:indexed-name": "Petryka R."}, {"@seq": "4", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Kuehbacher", "ce:indexed-name": "Kuehbacher T."}, {"@seq": "5", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Hebuterne", "ce:indexed-name": "Hebuterne X."}, {"@seq": "6", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Roblin", "ce:indexed-name": "Roblin X."}, {"@seq": "7", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Klopocka", "ce:indexed-name": "Klopocka M."}, {"@seq": "8", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Goldis", "ce:indexed-name": "Goldis A."}, {"@seq": "9", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Wisniewska-Jarosinska", "ce:indexed-name": "Wisniewska-Jarosinska M."}, {"@seq": "10", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Baranovsky", "ce:indexed-name": "Baranovsky A."}], "et-al": null}, "ref-sourcetitle": "Lancet"}}, {"ref-fulltext": "Sandborn, W.J., Feagan, B.G., Panes, J., D'Haens, G.R., Colombel, F.J., Zhou, Q., Huang, B., Enejosa, J.V., Pangan, A.L., Lacerda, A.P., Safety and efficacy of ABT-494 (upadacitinib), an oral JAK1 inhibitor, as induction therapy in patinets with Crohn's disease; results from CELEST (abstract). Gastroenterology 152 (2017), S1308\u2013S1309.", "@id": "12", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Safety and efficacy of ABT-494 (upadacitinib), an oral JAK1 inhibitor, as induction therapy in patinets with Crohn's disease; results from CELEST (abstract)"}, "refd-itemidlist": {"itemid": [{"$": "bib0320", "@idtype": "FRAGMENTID"}, {"$": "85028636028", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "152"}, "pagerange": {"@first": "S1308", "@last": "S1309"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W.J."}, {"@seq": "2", "ce:initials": "B.G.", "@_fa": "true", "ce:surname": "Feagan", "ce:indexed-name": "Feagan B.G."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Panes", "ce:indexed-name": "Panes J."}, {"@seq": "4", "ce:initials": "G.R.", "@_fa": "true", "ce:surname": "D'Haens", "ce:indexed-name": "D'Haens G.R."}, {"@seq": "5", "ce:initials": "F.J.", "@_fa": "true", "ce:surname": "Colombel", "ce:indexed-name": "Colombel F.J."}, {"@seq": "6", "ce:initials": "Q.", "@_fa": "true", "ce:surname": "Zhou", "ce:indexed-name": "Zhou Q."}, {"@seq": "7", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Huang", "ce:indexed-name": "Huang B."}, {"@seq": "8", "ce:initials": "J.V.", "@_fa": "true", "ce:surname": "Enejosa", "ce:indexed-name": "Enejosa J.V."}, {"@seq": "9", "ce:initials": "A.L.", "@_fa": "true", "ce:surname": "Pangan", "ce:indexed-name": "Pangan A.L."}, {"@seq": "10", "ce:initials": "A.P.", "@_fa": "true", "ce:surname": "Lacerda", "ce:indexed-name": "Lacerda A.P."}]}, "ref-sourcetitle": "Gastroenterology"}}, {"ref-fulltext": "Monteleone, G., Neurath, M.F., Ardizzone, S., Di Sabatino, A., Fantini, M.C., Castiglione, F., Scribano, M.L., Armuzzi, A., Caprioli, F., Sturniolo, G.C., et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med 372 (2015), 1104\u20131113.", "@id": "13", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease"}, "refd-itemidlist": {"itemid": [{"$": "bib0325", "@idtype": "FRAGMENTID"}, {"$": "84925064199", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "372"}, "pagerange": {"@first": "1104", "@last": "1113"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Monteleone", "ce:indexed-name": "Monteleone G."}, {"@seq": "2", "ce:initials": "M.F.", "@_fa": "true", "ce:surname": "Neurath", "ce:indexed-name": "Neurath M.F."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Ardizzone", "ce:indexed-name": "Ardizzone S."}, {"@seq": "4", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Di Sabatino", "ce:indexed-name": "Di Sabatino A."}, {"@seq": "5", "ce:initials": "M.C.", "@_fa": "true", "ce:surname": "Fantini", "ce:indexed-name": "Fantini M.C."}, {"@seq": "6", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Castiglione", "ce:indexed-name": "Castiglione F."}, {"@seq": "7", "ce:initials": "M.L.", "@_fa": "true", "ce:surname": "Scribano", "ce:indexed-name": "Scribano M.L."}, {"@seq": "8", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Armuzzi", "ce:indexed-name": "Armuzzi A."}, {"@seq": "9", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Caprioli", "ce:indexed-name": "Caprioli F."}, {"@seq": "10", "ce:initials": "G.C.", "@_fa": "true", "ce:surname": "Sturniolo", "ce:indexed-name": "Sturniolo G.C."}], "et-al": null}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "Vermeire, S., Oral SMAD7 antisense drug for Crohn's disease. N Engl J Med 372 (2015), 1166\u20131167.", "@id": "14", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Oral SMAD7 antisense drug for Crohn's disease"}, "refd-itemidlist": {"itemid": [{"$": "bib0330", "@idtype": "FRAGMENTID"}, {"$": "84925068548", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "372"}, "pagerange": {"@first": "1166", "@last": "1167"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Vermeire", "ce:indexed-name": "Vermeire S."}]}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "Feagan, B.G., Colombel, J.F., Rossiter, G., Li, X., Usiskin, K., Zhan, X., Sands, B.E., Correlation of clinical and endoscopic outcomes in patients with active Crohn's disease treated with mongersen (GED-0301) (abstract). Gastroentrology, 152, 2017 S-198.", "@id": "15", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Correlation of clinical and endoscopic outcomes in patients with active Crohn's disease treated with mongersen (GED-0301) (abstract)"}, "refd-itemidlist": {"itemid": [{"$": "bib0335", "@idtype": "FRAGMENTID"}, {"$": "85034988007", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "152"}}, "ref-text": "S-198", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.G.", "@_fa": "true", "ce:surname": "Feagan", "ce:indexed-name": "Feagan B.G."}, {"@seq": "2", "ce:initials": "J.F.", "@_fa": "true", "ce:surname": "Colombel", "ce:indexed-name": "Colombel J.F."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Rossiter", "ce:indexed-name": "Rossiter G."}, {"@seq": "4", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Li", "ce:indexed-name": "Li X."}, {"@seq": "5", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Usiskin", "ce:indexed-name": "Usiskin K."}, {"@seq": "6", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Zhan", "ce:indexed-name": "Zhan X."}, {"@seq": "7", "ce:initials": "B.E.", "@_fa": "true", "ce:surname": "Sands", "ce:indexed-name": "Sands B.E."}]}, "ref-sourcetitle": "Gastroentrology"}}, {"ref-fulltext": "Sandborn, W.J., Ghosh, S., Panes, J., Vranic, I., Su, C., Rousell, S., Niezychowski, W., Study, A.I., Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367 (2012), 616\u2013624.", "@id": "16", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis"}, "refd-itemidlist": {"itemid": [{"$": "bib0340", "@idtype": "FRAGMENTID"}, {"$": "84865013186", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "367"}, "pagerange": {"@first": "616", "@last": "624"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W.J."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Ghosh", "ce:indexed-name": "Ghosh S."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Panes", "ce:indexed-name": "Panes J."}, {"@seq": "4", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Vranic", "ce:indexed-name": "Vranic I."}, {"@seq": "5", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Su", "ce:indexed-name": "Su C."}, {"@seq": "6", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Rousell", "ce:indexed-name": "Rousell S."}, {"@seq": "7", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Niezychowski", "ce:indexed-name": "Niezychowski W."}, {"@seq": "8", "ce:initials": "A.I.", "@_fa": "true", "ce:surname": "Study", "ce:indexed-name": "Study A.I."}]}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "Sandborn, W.J., Su, C., Sands, B.E., D'Haens, G.R., Vermeire, S., Schreiber, S., Danese, S., Feagan, B.G., Reinisch, W., Niezychowski, W., et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376 (2017), 1723\u20131736 Integrated randomized clinical trials of tofacitinib demonstrating its effectiveness for induction and maintenance of remission in moderate to severe ulcerative colitis.", "@id": "17", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Tofacitinib as induction and maintenance therapy for ulcerative colitis"}, "refd-itemidlist": {"itemid": [{"$": "bib0345", "@idtype": "FRAGMENTID"}, {"$": "85019133160", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "376"}, "pagerange": {"@first": "1723", "@last": "1736"}}, "ref-text": "Integrated randomized clinical trials of tofacitinib demonstrating its effectiveness for induction and maintenance of remission in moderate to severe ulcerative colitis.", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W.J."}, {"@seq": "2", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Su", "ce:indexed-name": "Su C."}, {"@seq": "3", "ce:initials": "B.E.", "@_fa": "true", "ce:surname": "Sands", "ce:indexed-name": "Sands B.E."}, {"@seq": "4", "ce:initials": "G.R.", "@_fa": "true", "ce:surname": "D'Haens", "ce:indexed-name": "D'Haens G.R."}, {"@seq": "5", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Vermeire", "ce:indexed-name": "Vermeire S."}, {"@seq": "6", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Schreiber", "ce:indexed-name": "Schreiber S."}, {"@seq": "7", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Danese", "ce:indexed-name": "Danese S."}, {"@seq": "8", "ce:initials": "B.G.", "@_fa": "true", "ce:surname": "Feagan", "ce:indexed-name": "Feagan B.G."}, {"@seq": "9", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Reinisch", "ce:indexed-name": "Reinisch W."}, {"@seq": "10", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Niezychowski", "ce:indexed-name": "Niezychowski W."}], "et-al": null}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "Vermeire, S., O'Byrne, S., Keir, M., Williams, M., Lu, T.T., Mansfield, J.C., Lamb, C.A., Feagan, B.G., Panes, J., Salas, A., et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 384 (2014), 309\u2013318.", "@id": "18", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial"}, "refd-itemidlist": {"itemid": [{"$": "bib0350", "@idtype": "FRAGMENTID"}, {"$": "84904857048", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "384"}, "pagerange": {"@first": "309", "@last": "318"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Vermeire", "ce:indexed-name": "Vermeire S."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "O'Byrne", "ce:indexed-name": "O'Byrne S."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Keir", "ce:indexed-name": "Keir M."}, {"@seq": "4", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Williams", "ce:indexed-name": "Williams M."}, {"@seq": "5", "ce:initials": "T.T.", "@_fa": "true", "ce:surname": "Lu", "ce:indexed-name": "Lu T.T."}, {"@seq": "6", "ce:initials": "J.C.", "@_fa": "true", "ce:surname": "Mansfield", "ce:indexed-name": "Mansfield J.C."}, {"@seq": "7", "ce:initials": "C.A.", "@_fa": "true", "ce:surname": "Lamb", "ce:indexed-name": "Lamb C.A."}, {"@seq": "8", "ce:initials": "B.G.", "@_fa": "true", "ce:surname": "Feagan", "ce:indexed-name": "Feagan B.G."}, {"@seq": "9", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Panes", "ce:indexed-name": "Panes J."}, {"@seq": "10", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Salas", "ce:indexed-name": "Salas A."}], "et-al": null}, "ref-sourcetitle": "Lancet"}}, {"ref-fulltext": "Vermeire, S., Sandborn, W.J., Danese, S., Hebuterne, X., Salzberg, B.A., Klopocka, M., Tarabar, D., Vanasek, T., Gregus, M., Hellstern, P.A., et al. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 390 (2017), 135\u2013144.", "@id": "19", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial"}, "refd-itemidlist": {"itemid": [{"$": "bib0355", "@idtype": "FRAGMENTID"}, {"$": "85019363567", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "390"}, "pagerange": {"@first": "135", "@last": "144"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Vermeire", "ce:indexed-name": "Vermeire S."}, {"@seq": "2", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W.J."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Danese", "ce:indexed-name": "Danese S."}, {"@seq": "4", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Hebuterne", "ce:indexed-name": "Hebuterne X."}, {"@seq": "5", "ce:initials": "B.A.", "@_fa": "true", "ce:surname": "Salzberg", "ce:indexed-name": "Salzberg B.A."}, {"@seq": "6", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Klopocka", "ce:indexed-name": "Klopocka M."}, {"@seq": "7", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Tarabar", "ce:indexed-name": "Tarabar D."}, {"@seq": "8", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Vanasek", "ce:indexed-name": "Vanasek T."}, {"@seq": "9", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Gregus", "ce:indexed-name": "Gregus M."}, {"@seq": "10", "ce:initials": "P.A.", "@_fa": "true", "ce:surname": "Hellstern", "ce:indexed-name": "Hellstern P.A."}], "et-al": null}, "ref-sourcetitle": "Lancet"}}, {"ref-fulltext": "Sandborn, W.J., Feagan, B.G., Wolf, D.C., D'Haens, G., Vermeire, S., Hanauer, S.B., Ghosh, S., Smith, H., Cravets, M., Frohna, P.A., et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 374 (2016), 1754\u20131762.", "@id": "20", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "Ozanimod induction and maintenance treatment for ulcerative colitis"}, "refd-itemidlist": {"itemid": [{"$": "bib0360", "@idtype": "FRAGMENTID"}, {"$": "84968903266", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "374"}, "pagerange": {"@first": "1754", "@last": "1762"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W.J."}, {"@seq": "2", "ce:initials": "B.G.", "@_fa": "true", "ce:surname": "Feagan", "ce:indexed-name": "Feagan B.G."}, {"@seq": "3", "ce:initials": "D.C.", "@_fa": "true", "ce:surname": "Wolf", "ce:indexed-name": "Wolf D.C."}, {"@seq": "4", "ce:initials": "G.", "@_fa": "true", "ce:surname": "D'Haens", "ce:indexed-name": "D'Haens G."}, {"@seq": "5", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Vermeire", "ce:indexed-name": "Vermeire S."}, {"@seq": "6", "ce:initials": "S.B.", "@_fa": "true", "ce:surname": "Hanauer", "ce:indexed-name": "Hanauer S.B."}, {"@seq": "7", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Ghosh", "ce:indexed-name": "Ghosh S."}, {"@seq": "8", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Smith", "ce:indexed-name": "Smith H."}, {"@seq": "9", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Cravets", "ce:indexed-name": "Cravets M."}, {"@seq": "10", "ce:initials": "P.A.", "@_fa": "true", "ce:surname": "Frohna", "ce:indexed-name": "Frohna P.A."}], "et-al": null}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "Allen, P.B., Olivera, P., Emery, P., Moulin, D., Jouzeau, J.Y., Netter, P., Danese, S., Feagan, B., Sandborn, W.J., Peyrin-Biroulet, L., Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Aliment Pharmacol Ther 45 (2017), 1058\u20131072.", "@id": "21", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis"}, "refd-itemidlist": {"itemid": [{"$": "bib0365", "@idtype": "FRAGMENTID"}, {"$": "85014056418", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "45"}, "pagerange": {"@first": "1058", "@last": "1072"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.B.", "@_fa": "true", "ce:surname": "Allen", "ce:indexed-name": "Allen P.B."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Olivera", "ce:indexed-name": "Olivera P."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Emery", "ce:indexed-name": "Emery P."}, {"@seq": "4", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Moulin", "ce:indexed-name": "Moulin D."}, {"@seq": "5", "ce:initials": "J.Y.", "@_fa": "true", "ce:surname": "Jouzeau", "ce:indexed-name": "Jouzeau J.Y."}, {"@seq": "6", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Netter", "ce:indexed-name": "Netter P."}, {"@seq": "7", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Danese", "ce:indexed-name": "Danese S."}, {"@seq": "8", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Feagan", "ce:indexed-name": "Feagan B."}, {"@seq": "9", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W.J."}, {"@seq": "10", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Peyrin-Biroulet", "ce:indexed-name": "Peyrin-Biroulet L."}]}, "ref-sourcetitle": "Aliment Pharmacol Ther"}}, {"ref-fulltext": "Khanna, R., Bressler, B., Levesque, B.G., Zou, G., Stitt, L.W., Greenberg, G.R., Panaccione, R., Bitton, A., Pare, P., Vermeire, S., et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 386 (2015), 1825\u20131834.", "@id": "22", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial"}, "refd-itemidlist": {"itemid": [{"$": "bib0370", "@idtype": "FRAGMENTID"}, {"$": "84947036399", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "386"}, "pagerange": {"@first": "1825", "@last": "1834"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Khanna", "ce:indexed-name": "Khanna R."}, {"@seq": "2", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Bressler", "ce:indexed-name": "Bressler B."}, {"@seq": "3", "ce:initials": "B.G.", "@_fa": "true", "ce:surname": "Levesque", "ce:indexed-name": "Levesque B.G."}, {"@seq": "4", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Zou", "ce:indexed-name": "Zou G."}, {"@seq": "5", "ce:initials": "L.W.", "@_fa": "true", "ce:surname": "Stitt", "ce:indexed-name": "Stitt L.W."}, {"@seq": "6", "ce:initials": "G.R.", "@_fa": "true", "ce:surname": "Greenberg", "ce:indexed-name": "Greenberg G.R."}, {"@seq": "7", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Panaccione", "ce:indexed-name": "Panaccione R."}, {"@seq": "8", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Bitton", "ce:indexed-name": "Bitton A."}, {"@seq": "9", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Pare", "ce:indexed-name": "Pare P."}, {"@seq": "10", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Vermeire", "ce:indexed-name": "Vermeire S."}], "et-al": null}, "ref-sourcetitle": "Lancet"}}, {"ref-fulltext": "Colombel, JF PR, Bossuyt, P., Lukas, M., Baert, F.J., Vanasek, T., Danalioglu, A., Novacek, G., Armuzzi, A., Hebuterne, X., Superior endoscopic and deep remission outcomes in adults with moderate to severe Crohn's disease managed with treat to target approach versus clinical symptoms: data from CALM (abstract). Gastroenterology, 152, 2017 S-155.", "@id": "23", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Superior endoscopic and deep remission outcomes in adults with moderate to severe Crohn's disease managed with treat to target approach versus clinical symptoms: data from CALM (abstract)"}, "refd-itemidlist": {"itemid": [{"$": "bib0375", "@idtype": "FRAGMENTID"}, {"$": "85020845422", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "152"}}, "ref-text": "S-155", "ref-authors": {"author": [{"ce:given-name": "JF PR", "@seq": "1", "ce:initials": "J.P.", "@_fa": "true", "ce:surname": "Colombel", "ce:indexed-name": "Colombel J.P."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Bossuyt", "ce:indexed-name": "Bossuyt P."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Lukas", "ce:indexed-name": "Lukas M."}, {"@seq": "4", "ce:initials": "F.J.", "@_fa": "true", "ce:surname": "Baert", "ce:indexed-name": "Baert F.J."}, {"@seq": "5", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Vanasek", "ce:indexed-name": "Vanasek T."}, {"@seq": "6", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Danalioglu", "ce:indexed-name": "Danalioglu A."}, {"@seq": "7", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Novacek", "ce:indexed-name": "Novacek G."}, {"@seq": "8", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Armuzzi", "ce:indexed-name": "Armuzzi A."}, {"@seq": "9", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Hebuterne", "ce:indexed-name": "Hebuterne X."}]}, "ref-sourcetitle": "Gastroenterology"}}, {"ref-fulltext": "Williet, N., Sandborn, W.J., Peyrin-Biroulet, L., Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol, 12, 2014 1246-1256 e1246.", "@id": "24", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease"}, "refd-itemidlist": {"itemid": [{"$": "bib0380", "@idtype": "FRAGMENTID"}, {"$": "84904393612", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "12"}}, "ref-text": "1246-1256 e1246", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Williet", "ce:indexed-name": "Williet N."}, {"@seq": "2", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W.J."}, {"@seq": "3", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Peyrin-Biroulet", "ce:indexed-name": "Peyrin-Biroulet L."}]}, "ref-sourcetitle": "Clin Gastroenterol Hepatol"}}, {"ref-fulltext": "Peyrin-Biroulet, L., Sandborn, W., Sands, B.E., Reinisch, W., Bemelman, W., Bryant, R.V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110 (2015), 1324\u20131338 Consensus statements from international IBD experts based on literature review and expert opinion on which therapeutic targets are most relevant (short answer: clinical plus endoscopy or radiology).", "@id": "25", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"}, "refd-itemidlist": {"itemid": [{"$": "bib0385", "@idtype": "FRAGMENTID"}, {"$": "84941260661", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "110"}, "pagerange": {"@first": "1324", "@last": "1338"}}, "ref-text": "Consensus statements from international IBD experts based on literature review and expert opinion on which therapeutic targets are most relevant (short answer: clinical plus endoscopy or radiology).", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Peyrin-Biroulet", "ce:indexed-name": "Peyrin-Biroulet L."}, {"@seq": "2", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W."}, {"@seq": "3", "ce:initials": "B.E.", "@_fa": "true", "ce:surname": "Sands", "ce:indexed-name": "Sands B.E."}, {"@seq": "4", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Reinisch", "ce:indexed-name": "Reinisch W."}, {"@seq": "5", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Bemelman", "ce:indexed-name": "Bemelman W."}, {"@seq": "6", "ce:initials": "R.V.", "@_fa": "true", "ce:surname": "Bryant", "ce:indexed-name": "Bryant R.V."}, {"@seq": "7", "ce:initials": "G.", "@_fa": "true", "ce:surname": "D'Haens", "ce:indexed-name": "D'Haens G."}, {"@seq": "8", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Dotan", "ce:indexed-name": "Dotan I."}, {"@seq": "9", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Dubinsky", "ce:indexed-name": "Dubinsky M."}, {"@seq": "10", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Feagan", "ce:indexed-name": "Feagan B."}], "et-al": null}, "ref-sourcetitle": "Am J Gastroenterol"}}, {"ref-fulltext": "Singh, S., Pardi, D.S., Update on anti-tumor necrosis factor agents in Crohn disease. Gastroenterol Clin North Am 43 (2014), 457\u2013478.", "@id": "26", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Update on anti-tumor necrosis factor agents in Crohn disease"}, "refd-itemidlist": {"itemid": [{"$": "bib0390", "@idtype": "FRAGMENTID"}, {"$": "84905723625", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "43"}, "pagerange": {"@first": "457", "@last": "478"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Singh", "ce:indexed-name": "Singh S."}, {"@seq": "2", "ce:initials": "D.S.", "@_fa": "true", "ce:surname": "Pardi", "ce:indexed-name": "Pardi D.S."}]}, "ref-sourcetitle": "Gastroenterol Clin North Am"}}, {"ref-fulltext": "Yarur, A.J., Rubin, D.T., Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases. Inflamm Bowel Dis 21 (2015), 1709\u20131718.", "@id": "27", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases"}, "refd-itemidlist": {"itemid": [{"$": "bib0395", "@idtype": "FRAGMENTID"}, {"$": "84932174376", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "21"}, "pagerange": {"@first": "1709", "@last": "1718"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.J.", "@_fa": "true", "ce:surname": "Yarur", "ce:indexed-name": "Yarur A.J."}, {"@seq": "2", "ce:initials": "D.T.", "@_fa": "true", "ce:surname": "Rubin", "ce:indexed-name": "Rubin D.T."}]}, "ref-sourcetitle": "Inflamm Bowel Dis"}}, {"ref-fulltext": "Maser, E.A., Villela, R., Silverberg, M.S., Greenberg, G.R., Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 4 (2006), 1248\u20131254.", "@id": "28", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease"}, "refd-itemidlist": {"itemid": [{"$": "bib0400", "@idtype": "FRAGMENTID"}, {"$": "33749432435", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "4"}, "pagerange": {"@first": "1248", "@last": "1254"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.A.", "@_fa": "true", "ce:surname": "Maser", "ce:indexed-name": "Maser E.A."}, {"@seq": "2", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Villela", "ce:indexed-name": "Villela R."}, {"@seq": "3", "ce:initials": "M.S.", "@_fa": "true", "ce:surname": "Silverberg", "ce:indexed-name": "Silverberg M.S."}, {"@seq": "4", "ce:initials": "G.R.", "@_fa": "true", "ce:surname": "Greenberg", "ce:indexed-name": "Greenberg G.R."}]}, "ref-sourcetitle": "Clin Gastroenterol Hepatol"}}, {"ref-fulltext": "Seow, C.H., Newman, A., Irwin, S.P., Steinhart, A.H., Silverberg, M.S., Greenberg, G.R., Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 59 (2010), 49\u201354.", "@id": "29", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis"}, "refd-itemidlist": {"itemid": [{"$": "bib0405", "@idtype": "FRAGMENTID"}, {"$": "73449088039", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "59"}, "pagerange": {"@first": "49", "@last": "54"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.H.", "@_fa": "true", "ce:surname": "Seow", "ce:indexed-name": "Seow C.H."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Newman", "ce:indexed-name": "Newman A."}, {"@seq": "3", "ce:initials": "S.P.", "@_fa": "true", "ce:surname": "Irwin", "ce:indexed-name": "Irwin S.P."}, {"@seq": "4", "ce:initials": "A.H.", "@_fa": "true", "ce:surname": "Steinhart", "ce:indexed-name": "Steinhart A.H."}, {"@seq": "5", "ce:initials": "M.S.", "@_fa": "true", "ce:surname": "Silverberg", "ce:indexed-name": "Silverberg M.S."}, {"@seq": "6", "ce:initials": "G.R.", "@_fa": "true", "ce:surname": "Greenberg", "ce:indexed-name": "Greenberg G.R."}]}, "ref-sourcetitle": "Gut"}}, {"ref-fulltext": "Yarur, A.J., Kanagala, V., Stein, D.J., Czul, F., Quintero, M.A., Agrawal, D., Patel, A., Best, K., Fox, C., Idstein, K., et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. Aliment Pharmacol Ther 45 (2017), 933\u2013940.", "@id": "30", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease"}, "refd-itemidlist": {"itemid": [{"$": "bib0410", "@idtype": "FRAGMENTID"}, {"$": "85013449857", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "45"}, "pagerange": {"@first": "933", "@last": "940"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.J.", "@_fa": "true", "ce:surname": "Yarur", "ce:indexed-name": "Yarur A.J."}, {"@seq": "2", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Kanagala", "ce:indexed-name": "Kanagala V."}, {"@seq": "3", "ce:initials": "D.J.", "@_fa": "true", "ce:surname": "Stein", "ce:indexed-name": "Stein D.J."}, {"@seq": "4", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Czul", "ce:indexed-name": "Czul F."}, {"@seq": "5", "ce:initials": "M.A.", "@_fa": "true", "ce:surname": "Quintero", "ce:indexed-name": "Quintero M.A."}, {"@seq": "6", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Agrawal", "ce:indexed-name": "Agrawal D."}, {"@seq": "7", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Patel", "ce:indexed-name": "Patel A."}, {"@seq": "8", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Best", "ce:indexed-name": "Best K."}, {"@seq": "9", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Fox", "ce:indexed-name": "Fox C."}, {"@seq": "10", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Idstein", "ce:indexed-name": "Idstein K."}], "et-al": null}, "ref-sourcetitle": "Aliment Pharmacol Ther"}}, {"ref-fulltext": "Oh, E.H., Ko, D.H., Seo, H., Chang, K., Kim, G.U., Song, E.M., Seo, M., Lee, H.S., Hwang, S.W., Yang, D.H., et al. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease. World J Gastroenterol 23 (2017), 1489\u20131496.", "@id": "31", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease"}, "refd-itemidlist": {"itemid": [{"$": "bib0415", "@idtype": "FRAGMENTID"}, {"$": "85015061985", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "23"}, "pagerange": {"@first": "1489", "@last": "1496"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.H.", "@_fa": "true", "ce:surname": "Oh", "ce:indexed-name": "Oh E.H."}, {"@seq": "2", "ce:initials": "D.H.", "@_fa": "true", "ce:surname": "Ko", "ce:indexed-name": "Ko D.H."}, {"@seq": "3", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Seo", "ce:indexed-name": "Seo H."}, {"@seq": "4", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Chang", "ce:indexed-name": "Chang K."}, {"@seq": "5", "ce:initials": "G.U.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim G.U."}, {"@seq": "6", "ce:initials": "E.M.", "@_fa": "true", "ce:surname": "Song", "ce:indexed-name": "Song E.M."}, {"@seq": "7", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Seo", "ce:indexed-name": "Seo M."}, {"@seq": "8", "ce:initials": "H.S.", "@_fa": "true", "ce:surname": "Lee", "ce:indexed-name": "Lee H.S."}, {"@seq": "9", "ce:initials": "S.W.", "@_fa": "true", "ce:surname": "Hwang", "ce:indexed-name": "Hwang S.W."}, {"@seq": "10", "ce:initials": "D.H.", "@_fa": "true", "ce:surname": "Yang", "ce:indexed-name": "Yang D.H."}], "et-al": null}, "ref-sourcetitle": "World J Gastroenterol"}}, {"ref-fulltext": "Ward, M.G., Warner, B., Unsworth, N., Chuah, S.W., Brownclarke, C., Shieh, S., Parkes, M., Sanderson, J.D., Arkir, Z., Reynolds, J., et al. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther 46 (2017), 150\u2013161.", "@id": "32", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors"}, "refd-itemidlist": {"itemid": [{"$": "bib0420", "@idtype": "FRAGMENTID"}, {"$": "85019033667", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "46"}, "pagerange": {"@first": "150", "@last": "161"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.G.", "@_fa": "true", "ce:surname": "Ward", "ce:indexed-name": "Ward M.G."}, {"@seq": "2", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Warner", "ce:indexed-name": "Warner B."}, {"@seq": "3", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Unsworth", "ce:indexed-name": "Unsworth N."}, {"@seq": "4", "ce:initials": "S.W.", "@_fa": "true", "ce:surname": "Chuah", "ce:indexed-name": "Chuah S.W."}, {"@seq": "5", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Brownclarke", "ce:indexed-name": "Brownclarke C."}, {"@seq": "6", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Shieh", "ce:indexed-name": "Shieh S."}, {"@seq": "7", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Parkes", "ce:indexed-name": "Parkes M."}, {"@seq": "8", "ce:initials": "J.D.", "@_fa": "true", "ce:surname": "Sanderson", "ce:indexed-name": "Sanderson J.D."}, {"@seq": "9", "ce:initials": "Z.", "@_fa": "true", "ce:surname": "Arkir", "ce:indexed-name": "Arkir Z."}, {"@seq": "10", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Reynolds", "ce:indexed-name": "Reynolds J."}], "et-al": null}, "ref-sourcetitle": "Aliment Pharmacol Ther"}}, {"ref-fulltext": "Ward, M.G., Thwaites, P.A., Beswick, L., Hogg, J., Rosella, G., Van Langenberg, D., Reynolds, J., Gibson, P.R., Sparrow, M.P., Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. Aliment Pharmacol Ther 45 (2017), 1135\u20131145.", "@id": "33", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease"}, "refd-itemidlist": {"itemid": [{"$": "bib0425", "@idtype": "FRAGMENTID"}, {"$": "85013787029", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "45"}, "pagerange": {"@first": "1135", "@last": "1145"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.G.", "@_fa": "true", "ce:surname": "Ward", "ce:indexed-name": "Ward M.G."}, {"@seq": "2", "ce:initials": "P.A.", "@_fa": "true", "ce:surname": "Thwaites", "ce:indexed-name": "Thwaites P.A."}, {"@seq": "3", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Beswick", "ce:indexed-name": "Beswick L."}, {"@seq": "4", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Hogg", "ce:indexed-name": "Hogg J."}, {"@seq": "5", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Rosella", "ce:indexed-name": "Rosella G."}, {"@seq": "6", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Van Langenberg", "ce:indexed-name": "Van Langenberg D."}, {"@seq": "7", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Reynolds", "ce:indexed-name": "Reynolds J."}, {"@seq": "8", "ce:initials": "P.R.", "@_fa": "true", "ce:surname": "Gibson", "ce:indexed-name": "Gibson P.R."}, {"@seq": "9", "ce:initials": "M.P.", "@_fa": "true", "ce:surname": "Sparrow", "ce:indexed-name": "Sparrow M.P."}]}, "ref-sourcetitle": "Aliment Pharmacol Ther"}}, {"ref-fulltext": "Vande Casteele, N., Khanna, R., Therapeutic drug monitoring of golimumab in the treatment of ulcerative colitis. Pharm Res 34 (2017), 1556\u20131563.", "@id": "34", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Therapeutic drug monitoring of golimumab in the treatment of ulcerative colitis"}, "refd-itemidlist": {"itemid": [{"$": "bib0430", "@idtype": "FRAGMENTID"}, {"$": "85016929941", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "34"}, "pagerange": {"@first": "1556", "@last": "1563"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Vande Casteele", "ce:indexed-name": "Vande Casteele N."}, {"@seq": "2", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Khanna", "ce:indexed-name": "Khanna R."}]}, "ref-sourcetitle": "Pharm Res"}}, {"ref-fulltext": "Sandborn, W.J., Feagan, B.G., Rutgeerts, P., Hanauer, S., Colombel, J.F., Sands, B.E., Lukas, M., Fedorak, R.N., Lee, S., Bressler, B., et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 369 (2013), 711\u2013721.", "@id": "35", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Vedolizumab as induction and maintenance therapy for Crohn's disease"}, "refd-itemidlist": {"itemid": [{"$": "bib0435", "@idtype": "FRAGMENTID"}, {"$": "84882749768", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "369"}, "pagerange": {"@first": "711", "@last": "721"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Sandborn", "ce:indexed-name": "Sandborn W.J."}, {"@seq": "2", "ce:initials": "B.G.", "@_fa": "true", "ce:surname": "Feagan", "ce:indexed-name": "Feagan B.G."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Rutgeerts", "ce:indexed-name": "Rutgeerts P."}, {"@seq": "4", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Hanauer", "ce:indexed-name": "Hanauer S."}, {"@seq": "5", "ce:initials": "J.F.", "@_fa": "true", "ce:surname": "Colombel", "ce:indexed-name": "Colombel J.F."}, {"@seq": "6", "ce:initials": "B.E.", "@_fa": "true", "ce:surname": "Sands", "ce:indexed-name": "Sands B.E."}, {"@seq": "7", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Lukas", "ce:indexed-name": "Lukas M."}, {"@seq": "8", "ce:initials": "R.N.", "@_fa": "true", "ce:surname": "Fedorak", "ce:indexed-name": "Fedorak R.N."}, {"@seq": "9", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Lee", "ce:indexed-name": "Lee S."}, {"@seq": "10", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Bressler", "ce:indexed-name": "Bressler B."}], "et-al": null}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "Battat, R., Kopylov, U., Bessissow, T., Bitton, A., Cohen, A., Jain, A., Martel, M., Seidman, E., Afif, W., Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn's disease. Clin Gastroenterol Hepatol, 15, 2017 1427-1434 e1422.", "@id": "36", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn's disease"}, "refd-itemidlist": {"itemid": [{"$": "bib0440", "@idtype": "FRAGMENTID"}, {"$": "85027573700", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "15"}}, "ref-text": "1427-1434 e1422", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Battat", "ce:indexed-name": "Battat R."}, {"@seq": "2", "ce:initials": "U.", "@_fa": "true", "ce:surname": "Kopylov", "ce:indexed-name": "Kopylov U."}, {"@seq": "3", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Bessissow", "ce:indexed-name": "Bessissow T."}, {"@seq": "4", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Bitton", "ce:indexed-name": "Bitton A."}, {"@seq": "5", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Cohen", "ce:indexed-name": "Cohen A."}, {"@seq": "6", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Jain", "ce:indexed-name": "Jain A."}, {"@seq": "7", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Martel", "ce:indexed-name": "Martel M."}, {"@seq": "8", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Seidman", "ce:indexed-name": "Seidman E."}, {"@seq": "9", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Afif", "ce:indexed-name": "Afif W."}]}, "ref-sourcetitle": "Clin Gastroenterol Hepatol"}}, {"ref-fulltext": "Liefferinckx, C., Minsart, C., Toubeau, J.F., Cremer, A., Amininejad, L., Quertinmont, E., Deviere, J., Gils, A., van Gossum, A., Franchimont, D., Infliximab trough levels at induction to predict treatment failure during maintenance. Inflamm Bowel Dis 23 (2017), 1371\u20131381.", "@id": "37", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Infliximab trough levels at induction to predict treatment failure during maintenance"}, "refd-itemidlist": {"itemid": [{"$": "bib0445", "@idtype": "FRAGMENTID"}, {"$": "85026480618", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "23"}, "pagerange": {"@first": "1371", "@last": "1381"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Liefferinckx", "ce:indexed-name": "Liefferinckx C."}, {"@seq": "2", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Minsart", "ce:indexed-name": "Minsart C."}, {"@seq": "3", "ce:initials": "J.F.", "@_fa": "true", "ce:surname": "Toubeau", "ce:indexed-name": "Toubeau J.F."}, {"@seq": "4", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Cremer", "ce:indexed-name": "Cremer A."}, {"@seq": "5", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Amininejad", "ce:indexed-name": "Amininejad L."}, {"@seq": "6", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Quertinmont", "ce:indexed-name": "Quertinmont E."}, {"@seq": "7", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Deviere", "ce:indexed-name": "Deviere J."}, {"@seq": "8", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Gils", "ce:indexed-name": "Gils A."}, {"@seq": "9", "ce:initials": "A.", "@_fa": "true", "ce:surname": "van Gossum", "ce:indexed-name": "van Gossum A."}, {"@seq": "10", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Franchimont", "ce:indexed-name": "Franchimont D."}]}, "ref-sourcetitle": "Inflamm Bowel Dis"}}, {"ref-fulltext": "Kelly, O.B., Donnell, S.O., Stempak, J.M., Steinhart, A.H., Silverberg, M.S., Therapeutic drug monitoring to guide infliximab dose adjustment is associated with better endoscopic outcomes than clinical decision making alone in active inflammatory bowel disease. Inflamm Bowel Dis 23 (2017), 1202\u20131209.", "@id": "38", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Therapeutic drug monitoring to guide infliximab dose adjustment is associated with better endoscopic outcomes than clinical decision making alone in active inflammatory bowel disease"}, "refd-itemidlist": {"itemid": [{"$": "bib0450", "@idtype": "FRAGMENTID"}, {"$": "85021277021", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "23"}, "pagerange": {"@first": "1202", "@last": "1209"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "O.B.", "@_fa": "true", "ce:surname": "Kelly", "ce:indexed-name": "Kelly O.B."}, {"@seq": "2", "ce:initials": "S.O.", "@_fa": "true", "ce:surname": "Donnell", "ce:indexed-name": "Donnell S.O."}, {"@seq": "3", "ce:initials": "J.M.", "@_fa": "true", "ce:surname": "Stempak", "ce:indexed-name": "Stempak J.M."}, {"@seq": "4", "ce:initials": "A.H.", "@_fa": "true", "ce:surname": "Steinhart", "ce:indexed-name": "Steinhart A.H."}, {"@seq": "5", "ce:initials": "M.S.", "@_fa": "true", "ce:surname": "Silverberg", "ce:indexed-name": "Silverberg M.S."}]}, "ref-sourcetitle": "Inflamm Bowel Dis"}}, {"ref-fulltext": "Vande Casteele, N., Ferrante, M., Van Assche, G., Ballet, V., Compernolle, G., Van Steen, K., Simoens, S., Rutgeerts, P., Gils, A., Vermeire, S., Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology, 148, 2015 1320-1329 e1323 Complicated prospective trial of therapeutic drug monitoring in IBD patients on infliximab suggesting that dose optimization of infliximab trough to 3\u20137 mcg/mL results in clinical improvement.", "@id": "39", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease"}, "refd-itemidlist": {"itemid": [{"$": "bib0455", "@idtype": "FRAGMENTID"}, {"$": "84930015437", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "148"}}, "ref-text": "1320-1329 e1323 Complicated prospective trial of therapeutic drug monitoring in IBD patients on infliximab suggesting that dose optimization of infliximab trough to 3\u20137 mcg/mL results in clinical improvement.", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Vande Casteele", "ce:indexed-name": "Vande Casteele N."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Ferrante", "ce:indexed-name": "Ferrante M."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Van Assche", "ce:indexed-name": "Van Assche G."}, {"@seq": "4", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Ballet", "ce:indexed-name": "Ballet V."}, {"@seq": "5", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Compernolle", "ce:indexed-name": "Compernolle G."}, {"@seq": "6", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Van Steen", "ce:indexed-name": "Van Steen K."}, {"@seq": "7", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Simoens", "ce:indexed-name": "Simoens S."}, {"@seq": "8", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Rutgeerts", "ce:indexed-name": "Rutgeerts P."}, {"@seq": "9", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Gils", "ce:indexed-name": "Gils A."}, {"@seq": "10", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Vermeire", "ce:indexed-name": "Vermeire S."}]}, "ref-sourcetitle": "Gastroenterology"}}, {"ref-fulltext": "Ben-Horin, S., Drug level-based anti-tumor necrosis factor therapy: ready for prime time?. Gastroenterology 148 (2015), 1268\u20131271.", "@id": "40", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Drug level-based anti-tumor necrosis factor therapy: ready for prime time?"}, "refd-itemidlist": {"itemid": [{"$": "bib0460", "@idtype": "FRAGMENTID"}, {"$": "84930014117", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "148"}, "pagerange": {"@first": "1268", "@last": "1271"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Ben-Horin", "ce:indexed-name": "Ben-Horin S."}]}, "ref-sourcetitle": "Gastroenterology"}}, {"ref-fulltext": "Nanda, K.S., Cheifetz, A.S., Moss, A.C., Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 108 (2013), 40\u201347 quiz 48.", "@id": "41", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis"}, "refd-itemidlist": {"itemid": [{"$": "bib0465", "@idtype": "FRAGMENTID"}, {"$": "84872050633", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "108"}, "pagerange": {"@first": "40", "@last": "47"}}, "ref-text": "quiz 48", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "K.S.", "@_fa": "true", "ce:surname": "Nanda", "ce:indexed-name": "Nanda K.S."}, {"@seq": "2", "ce:initials": "A.S.", "@_fa": "true", "ce:surname": "Cheifetz", "ce:indexed-name": "Cheifetz A.S."}, {"@seq": "3", "ce:initials": "A.C.", "@_fa": "true", "ce:surname": "Moss", "ce:indexed-name": "Moss A.C."}]}, "ref-sourcetitle": "Am J Gastroenterol"}}, {"ref-fulltext": "Ungar, B., Chowers, Y., Yavzori, M., Picard, O., Fudim, E., Har-Noy, O., Kopylov, U., Eliakim, R., Ben-Horin, S., Consortium A: the temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 63 (2014), 1258\u20131264.", "@id": "42", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Consortium A: the temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab"}, "refd-itemidlist": {"itemid": [{"$": "bib0470", "@idtype": "FRAGMENTID"}, {"$": "84904063633", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "63"}, "pagerange": {"@first": "1258", "@last": "1264"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Ungar", "ce:indexed-name": "Ungar B."}, {"@seq": "2", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Chowers", "ce:indexed-name": "Chowers Y."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Yavzori", "ce:indexed-name": "Yavzori M."}, {"@seq": "4", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Picard", "ce:indexed-name": "Picard O."}, {"@seq": "5", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Fudim", "ce:indexed-name": "Fudim E."}, {"@seq": "6", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Har-Noy", "ce:indexed-name": "Har-Noy O."}, {"@seq": "7", "ce:initials": "U.", "@_fa": "true", "ce:surname": "Kopylov", "ce:indexed-name": "Kopylov U."}, {"@seq": "8", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Eliakim", "ce:indexed-name": "Eliakim R."}, {"@seq": "9", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Ben-Horin", "ce:indexed-name": "Ben-Horin S."}]}, "ref-sourcetitle": "Gut"}}, {"ref-fulltext": "Van Stappen, T., Vande Casteele, N., Van Assche, G., Ferrante, M., Vermeire, S., Gils, A., Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. Gut, 2017 Apr 27 pii: gutjnl-2016-313071.", "@id": "43", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial"}, "refd-itemidlist": {"itemid": [{"$": "bib0475", "@idtype": "FRAGMENTID"}, {"$": "85030719880", "@idtype": "SGR"}]}, "ref-text": "pii: gutjnl-2016-313071", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Van Stappen", "ce:indexed-name": "Van Stappen T."}, {"@seq": "2", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Vande Casteele", "ce:indexed-name": "Vande Casteele N."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Van Assche", "ce:indexed-name": "Van Assche G."}, {"@seq": "4", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Ferrante", "ce:indexed-name": "Ferrante M."}, {"@seq": "5", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Vermeire", "ce:indexed-name": "Vermeire S."}, {"@seq": "6", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Gils", "ce:indexed-name": "Gils A."}]}, "ref-sourcetitle": "Gut"}}, {"ref-fulltext": "Silva-Ferreira, F., Afonso, J., Pinto-Lopes, P., Magro, F., A systematic review on infliximab and adalimumab drug monitoring: levels, clinical outcomes and assays. Inflamm Bowel Dis 22 (2016), 2289\u20132301.", "@id": "44", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "A systematic review on infliximab and adalimumab drug monitoring: levels, clinical outcomes and assays"}, "refd-itemidlist": {"itemid": [{"$": "bib0480", "@idtype": "FRAGMENTID"}, {"$": "84983672130", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "22"}, "pagerange": {"@first": "2289", "@last": "2301"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Silva-Ferreira", "ce:indexed-name": "Silva-Ferreira F."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Afonso", "ce:indexed-name": "Afonso J."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Pinto-Lopes", "ce:indexed-name": "Pinto-Lopes P."}, {"@seq": "4", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Magro", "ce:indexed-name": "Magro F."}]}, "ref-sourcetitle": "Inflamm Bowel Dis"}}, {"ref-fulltext": "Park, D.I., Current status of biosimilars in the treatment of inflammatory bowel diseases. Intest Res 14 (2016), 15\u201320.", "@id": "45", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "Current status of biosimilars in the treatment of inflammatory bowel diseases"}, "refd-itemidlist": {"itemid": [{"$": "bib0485", "@idtype": "FRAGMENTID"}, {"$": "85005975905", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "14"}, "pagerange": {"@first": "15", "@last": "20"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.I.", "@_fa": "true", "ce:surname": "Park", "ce:indexed-name": "Park D.I."}]}, "ref-sourcetitle": "Intest Res"}}, {"ref-fulltext": "US Food and Drug Administration. Guidance for industry: quality considerations in demonstrating biosimilarity to a therapeutic protein product to a reference product. https://www.fda.gov/downloads/drugs/guidances/ucm291134.pdf Published 2015. Assessed May 16, 2017.", "@id": "46", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-website": {"ce:e-address": {"$": "https://www.fda.gov/downloads/drugs/guidances/ucm291134.pdf", "@type": "email"}}, "refd-itemidlist": {"itemid": [{"$": "bib0490", "@idtype": "FRAGMENTID"}, {"$": "85030696718", "@idtype": "SGR"}]}, "ref-text": "Drug Administration. Guidance for industry: quality considerations in demonstrating biosimilarity to a therapeutic protein product to a reference product. Published 2015. Assessed May 16.", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "U.S.", "@_fa": "true", "ce:surname": "Food", "ce:indexed-name": "Food U.S."}]}}}, {"ref-fulltext": "McCamish, M., Woollett, G., The state of the art in the development of biosimilars. Clin Pharmacol Ther 91 (2012), 405\u2013417.", "@id": "47", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "The state of the art in the development of biosimilars"}, "refd-itemidlist": {"itemid": [{"$": "bib0495", "@idtype": "FRAGMENTID"}, {"$": "84857233319", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "91"}, "pagerange": {"@first": "405", "@last": "417"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "McCamish", "ce:indexed-name": "McCamish M."}, {"@seq": "2", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Woollett", "ce:indexed-name": "Woollett G."}]}, "ref-sourcetitle": "Clin Pharmacol Ther"}}, {"ref-fulltext": "Yoo, D.H., Racewicz, A., Brzezicki, J., Yatsyshyn, R., Arteaga, E.T., Baranauskaite, A., Abud-Mendoza, C., Navarra, S., Kadinov, V., Sariego, I.G., et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther, 18, 2016, 82.", "@id": "48", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study"}, "refd-itemidlist": {"itemid": [{"$": "bib0500", "@idtype": "FRAGMENTID"}, {"$": "84962037330", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "18"}, "pagerange": {"@first": "82"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.H.", "@_fa": "true", "ce:surname": "Yoo", "ce:indexed-name": "Yoo D.H."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Racewicz", "ce:indexed-name": "Racewicz A."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Brzezicki", "ce:indexed-name": "Brzezicki J."}, {"@seq": "4", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Yatsyshyn", "ce:indexed-name": "Yatsyshyn R."}, {"@seq": "5", "ce:initials": "E.T.", "@_fa": "true", "ce:surname": "Arteaga", "ce:indexed-name": "Arteaga E.T."}, {"@seq": "6", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Baranauskaite", "ce:indexed-name": "Baranauskaite A."}, {"@seq": "7", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Abud-Mendoza", "ce:indexed-name": "Abud-Mendoza C."}, {"@seq": "8", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Navarra", "ce:indexed-name": "Navarra S."}, {"@seq": "9", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Kadinov", "ce:indexed-name": "Kadinov V."}, {"@seq": "10", "ce:initials": "I.G.", "@_fa": "true", "ce:surname": "Sariego", "ce:indexed-name": "Sariego I.G."}], "et-al": null}, "ref-sourcetitle": "Arthritis Res Ther"}}, {"ref-fulltext": "Komaki, Y., Yamada, A., Komaki, F., Micic, D., Ido, A., Sakuraba, A., Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther 45 (2017), 1043\u20131057.", "@id": "49", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases"}, "refd-itemidlist": {"itemid": [{"$": "bib0505", "@idtype": "FRAGMENTID"}, {"$": "85013822025", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "45"}, "pagerange": {"@first": "1043", "@last": "1057"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Komaki", "ce:indexed-name": "Komaki Y."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Yamada", "ce:indexed-name": "Yamada A."}, {"@seq": "3", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Komaki", "ce:indexed-name": "Komaki F."}, {"@seq": "4", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Micic", "ce:indexed-name": "Micic D."}, {"@seq": "5", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Ido", "ce:indexed-name": "Ido A."}, {"@seq": "6", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Sakuraba", "ce:indexed-name": "Sakuraba A."}]}, "ref-sourcetitle": "Aliment Pharmacol Ther"}}, {"ref-fulltext": "Kim, Y.H., Ye, B.D., Pesegova, M., Alexeva, O., Osipenko, M., Lahat, A., Dofofeyev, A., Salamon, A., Fishman, S., Levchenko, O., et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results (abstract). Gastroenterology, 152, 2017, S65.", "@id": "50", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results (abstract)"}, "refd-itemidlist": {"itemid": [{"$": "bib0510", "@idtype": "FRAGMENTID"}, {"$": "85030721724", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "152"}, "pagerange": {"@first": "S65"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "Y.H.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim Y.H."}, {"@seq": "2", "ce:initials": "B.D.", "@_fa": "true", "ce:surname": "Ye", "ce:indexed-name": "Ye B.D."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Pesegova", "ce:indexed-name": "Pesegova M."}, {"@seq": "4", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Alexeva", "ce:indexed-name": "Alexeva O."}, {"@seq": "5", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Osipenko", "ce:indexed-name": "Osipenko M."}, {"@seq": "6", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Lahat", "ce:indexed-name": "Lahat A."}, {"@seq": "7", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Dofofeyev", "ce:indexed-name": "Dofofeyev A."}, {"@seq": "8", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Salamon", "ce:indexed-name": "Salamon A."}, {"@seq": "9", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Fishman", "ce:indexed-name": "Fishman S."}, {"@seq": "10", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Levchenko", "ce:indexed-name": "Levchenko O."}], "et-al": null}, "ref-sourcetitle": "Gastroenterology"}}, {"ref-fulltext": "Jorgensen, K.K., Olsen, I.C., Goll, G.L., Lorentzen, M., Bolstad, N., Haavardsholm, E.A., Lundin, K.E.A., Mork, C., Jahnsen, J., Kvien, T.K., et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 389 (2017), 2304\u20132316 Randomized trial sponsored by Norwegian government of continuing originator infliximab versus switching to biosimilar CT-P13 across various indications found no differences in overall clinical worsening.", "@id": "51", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial"}, "refd-itemidlist": {"itemid": [{"$": "bib0515", "@idtype": "FRAGMENTID"}, {"$": "85019086175", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "389"}, "pagerange": {"@first": "2304", "@last": "2316"}}, "ref-text": "Randomized trial sponsored by Norwegian government of continuing originator infliximab versus switching to biosimilar CT-P13 across various indications found no differences in overall clinical worsening.", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "K.K.", "@_fa": "true", "ce:surname": "Jorgensen", "ce:indexed-name": "Jorgensen K.K."}, {"@seq": "2", "ce:initials": "I.C.", "@_fa": "true", "ce:surname": "Olsen", "ce:indexed-name": "Olsen I.C."}, {"@seq": "3", "ce:initials": "G.L.", "@_fa": "true", "ce:surname": "Goll", "ce:indexed-name": "Goll G.L."}, {"@seq": "4", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Lorentzen", "ce:indexed-name": "Lorentzen M."}, {"@seq": "5", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Bolstad", "ce:indexed-name": "Bolstad N."}, {"@seq": "6", "ce:initials": "E.A.", "@_fa": "true", "ce:surname": "Haavardsholm", "ce:indexed-name": "Haavardsholm E.A."}, {"@seq": "7", "ce:initials": "K.E.A.", "@_fa": "true", "ce:surname": "Lundin", "ce:indexed-name": "Lundin K.E.A."}, {"@seq": "8", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Mork", "ce:indexed-name": "Mork C."}, {"@seq": "9", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Jahnsen", "ce:indexed-name": "Jahnsen J."}, {"@seq": "10", "ce:initials": "T.K.", "@_fa": "true", "ce:surname": "Kvien", "ce:indexed-name": "Kvien T.K."}], "et-al": null}, "ref-sourcetitle": "Lancet"}}, {"ref-fulltext": "Joergensen, K.K., Olsen, I.C., Goll, G.L., Lorentzen, M., Bolstad, N., Berset, I.P., Haavardsholm, E.A., Lundin, K.E., M\u00f8rk, C., Kvien, T.K., et al. Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the Nor-Switch Trial (abstract). Gastroenterology 152 (2017), S65\u2013S66.", "@id": "52", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-title": {"ref-titletext": "Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the Nor-Switch Trial (abstract)"}, "refd-itemidlist": {"itemid": [{"$": "bib0520", "@idtype": "FRAGMENTID"}, {"$": "85030683368", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "152"}, "pagerange": {"@first": "S65", "@last": "S66"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "K.K.", "@_fa": "true", "ce:surname": "Joergensen", "ce:indexed-name": "Joergensen K.K."}, {"@seq": "2", "ce:initials": "I.C.", "@_fa": "true", "ce:surname": "Olsen", "ce:indexed-name": "Olsen I.C."}, {"@seq": "3", "ce:initials": "G.L.", "@_fa": "true", "ce:surname": "Goll", "ce:indexed-name": "Goll G.L."}, {"@seq": "4", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Lorentzen", "ce:indexed-name": "Lorentzen M."}, {"@seq": "5", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Bolstad", "ce:indexed-name": "Bolstad N."}, {"@seq": "6", "ce:initials": "I.P.", "@_fa": "true", "ce:surname": "Berset", "ce:indexed-name": "Berset I.P."}, {"@seq": "7", "ce:initials": "E.A.", "@_fa": "true", "ce:surname": "Haavardsholm", "ce:indexed-name": "Haavardsholm E.A."}, {"@seq": "8", "ce:initials": "K.E.", "@_fa": "true", "ce:surname": "Lundin", "ce:indexed-name": "Lundin K.E."}, {"@seq": "9", "ce:initials": "C.", "@_fa": "true", "ce:surname": "M\u00f8rk", "ce:indexed-name": "Mork C."}, {"@seq": "10", "ce:initials": "T.K.", "@_fa": "true", "ce:surname": "Kvien", "ce:indexed-name": "Kvien T.K."}], "et-al": null}, "ref-sourcetitle": "Gastroenterology"}}]}}}}, "affiliation": [{"affiliation-city": "Bangkok", "@id": "60028190", "affilname": "Chulalongkorn University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190", "affiliation-country": "Thailand"}, {"affiliation-city": "Seoul", "@id": "60006240", "affilname": "University of Ulsan College of Medicine", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006240", "affiliation-country": "South Korea"}, {"affiliation-city": "Rochester", "@id": "60005558", "affilname": "Mayo Clinic", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005558", "affiliation-country": "United States"}], "coredata": {"srctype": "j", "eid": "2-s2.0-85030719959", "dc:description": "For the ultimate aim of preventing intestinal disability in inflammatory bowel disease (IBD), the treatment goal has moved from symptom control towards inflammation control (i.e., \u2018deep remission\u2019). Furthermore, the concept of \u2018treat-to-target\u2019 has been adopted to assist in treatment escalation and better control. Although deep remission is possible with current biologics, there are still unmet needs in IBD management. Biosimilars of several biologics will be an increasingly common option in the near future. In this review, we review the current status of novel drugs for IBD, focusing on recent phase 2 and 3 randomized controlled trials, and address the issues of biosimilars. Recent studies of the \u2018treat-to-target\u2019 strategy and therapeutic drug monitoring are summarized.", "pubmed-id": "28992449", "prism:coverDate": "2017-12-01", "prism:aggregationType": "Journal", "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85030719959", "dc:creator": {"author": [{"ce:given-name": "Sang Hyoung", "preferred-name": {"ce:given-name": "Sang Hyoung", "ce:initials": "S.H.", "ce:surname": "Park", "ce:indexed-name": "Park S.H."}, "@seq": "1", "ce:initials": "S.H.", "@_fa": "true", "affiliation": [{"@id": "60005558", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005558"}, {"@id": "60006240", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006240"}], "ce:surname": "Park", "@auid": "34977204700", "author-url": "https://api.elsevier.com/content/author/author_id/34977204700", "ce:indexed-name": "Park S.H."}]}, "link": [{"@_fa": "true", "@rel": "self", "@href": "https://api.elsevier.com/content/abstract/scopus_id/85030719959"}, {"@_fa": "true", "@rel": "scopus", "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85030719959&origin=inward"}, {"@_fa": "true", "@rel": "scopus-citedby", "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85030719959&origin=inward"}], "source-id": "20681", "pii": "S1471489217300619", "citedby-count": "13", "prism:volume": "37", "subtype": "re", "dc:title": "Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease", "openaccess": "0", "prism:issn": "14714973 14714892", "publishercopyright": "\u00a9 2017 Elsevier Ltd", "subtypeDescription": "Review", "prism:publicationName": "Current Opinion in Pharmacology", "prism:pageRange": "65-71", "prism:endingPage": "71", "openaccessFlag": "false", "prism:doi": "10.1016/j.coph.2017.09.007", "prism:startingPage": "65", "dc:identifier": "SCOPUS_ID:85030719959", "dc:publisher": "Elsevier Ltd"}, "idxterms": {"mainterm": [{"$": "Anti-Inflammatory Agents", "@weight": "b", "@candidate": "n"}, {"$": "Biological Products", "@weight": "b", "@candidate": "n"}, {"$": "Biosimilar Pharmaceuticals", "@weight": "b", "@candidate": "n"}, {"$": "Drug Monitoring", "@weight": "b", "@candidate": "n"}, {"$": "Humans", "@weight": "b", "@candidate": "n"}, {"$": "Inflammatory Bowel Diseases", "@weight": "b", "@candidate": "n"}]}, "language": {"@xml:lang": "eng"}, "authkeywords": null, "subject-areas": {"subject-area": [{"@_fa": "true", "$": "Pharmacology", "@code": "3004", "@abbrev": "PHAR"}, {"@_fa": "true", "$": "Drug Discovery", "@code": "3002", "@abbrev": "PHAR"}]}, "authors": {"author": [{"ce:given-name": "Sang Hyoung", "preferred-name": {"ce:given-name": "Sang Hyoung", "ce:initials": "S.H.", "ce:surname": "Park", "ce:indexed-name": "Park S.H."}, "@seq": "1", "ce:initials": "S.H.", "@_fa": "true", "affiliation": [{"@id": "60005558", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005558"}, {"@id": "60006240", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006240"}], "ce:surname": "Park", "@auid": "34977204700", "author-url": "https://api.elsevier.com/content/author/author_id/34977204700", "ce:indexed-name": "Park S.H."}, {"ce:given-name": "Satimai", "preferred-name": {"ce:given-name": "Satimai", "ce:initials": "S.", "ce:surname": "Aniwan", "ce:indexed-name": "Aniwan S."}, "@seq": "2", "ce:initials": "S.", "@_fa": "true", "affiliation": [{"@id": "60005558", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005558"}, {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}], "ce:surname": "Aniwan", "@auid": "36010544000", "author-url": "https://api.elsevier.com/content/author/author_id/36010544000", "ce:indexed-name": "Aniwan S."}, {"ce:given-name": "Edward V", "preferred-name": {"ce:given-name": "Edward V.", "ce:initials": "E.V.", "ce:surname": "Loftus", "ce:indexed-name": "Loftus E.V."}, "@seq": "3", "ce:initials": "E.V.", "@_fa": "true", "affiliation": {"@id": "60005558", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005558"}, "ce:surname": "Loftus", "@auid": "7202138774", "ce:suffix": "Jr", "author-url": "https://api.elsevier.com/content/author/author_id/7202138774", "ce:indexed-name": "Loftus E.V."}]}}}